FTO and acute myeloid leukemia: Suppression of FTO genetically or pharmacologically significantly sensitizes the two Ara-C-resistant cell lines to Ara-C, suggesting a potentially druggable target of FTO in the treatment of Ara-C resistance in t(8;21) AML.